European Commission Approves Merck's Bavencio for Maintenance Treatment in Advanced Urothelial Carcinoma
The European Commission has approved Merck's Bavencio (avelumab) as a first-line maintenance therapy for adults with locally advanced or metastatic urothelial carcinoma who have not progressed after platinum-based chemotherapy. This decision is supported by results from the Phase III JAVELIN Bladder 100 trial, which showed improved overall survival...
- Published date: 24-07-2026 10:02 AM
The European Commission has granted approval for Merck's Bavencio (avelumab) as a first-line maintenance treatment for adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.
This decision follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) and is based on data from the Phase III JAVELIN Bladder 100 study, which demonstrated a significant improvement in overall survival for patients receiving Bavencio compared to best supportive care alone.
The approval provides a new treatment option for healthcare professionals managing advanced bladder cancer across the European Union, expanding therapeutic strategies for this patient population.
The European Commission has approved Merck's Bavencio (avelumab) as a first-line maintenance therapy for adults with locally advanced or metastatic urothelial carcinoma who have not progressed after platinum-based chemotherapy. This decision is supported by results from the Phase III JAVELIN Bladder 100 trial, which showed improved overall survival. The approval offers clinicians across the EU a new option for managing advanced bladder cancer.